ACTIVE GYN/ONC CLINICAL TRIALS

CERVICAL STUDIES

GOG-237	Comparative Analysis of CA-IX, p16, Proliferative Markers & HPV in the Dx of Significant Cervical Lesions in Pts w a Cytologic Dx of Atypical Glandular Cells (AGC)	IRB approved thru 10/22/11
	(IRB#09-310)	
GOG-240	Randomized Phase III Trial of Cisplatin + Paclitaxel with and without NCI-Supplied	IRB approved
	Bevacizumab (IND#7921) vs the Non-Platinum Doublet, Topotecan + Paclitaxel, with	thru 5/31/11
	and without NCI- Supplied Bevacizumab in Stage IVB, recurrent or Persistent	
	Carcinoma of the Cervix	
	(IRB#09-126)	
GOG-263	Randomized Phase III Trial of Adjuvant Radiation vs Chemoradiation in Intermediate	IRB approved
	Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and	thru 3/11/2012
	Pelvic Lymphadenectomy (IRB#11-038)	

CORPUS UTERUS & ENDOMETRIAL

GOG-0086P	3 Arm Randomized Phase II Study of Paclitaxel/Carbo/Bevacizumab,	IRB approved
	Paclitaxel/Carbo/Temsirolimus and Ixabepilone/Carbo/Bevacizumab as Initial Therapy	thru 9/30/11
	for Measurable Stage III or IVA, IVB, or Recurrent Endometrial Cancer	
	(IRB#09-285)	
GOG-249	A Phase III Trial of Pelvic Radiation Therapy Versus Vaginal Cuff Brachytherapy	IRB approved
	Followed by Paclitaxel/Carboplatin Chemotherapy in Patients with High Risk, Early	thru 12/17/11
	Stage Endometrial Carcinoma	
	(IRB#10-020)	
GOG-258	Randomized Phase III of Cisplatin & Tumor Volume Directed Irradiation Followed by	IRB approved
	Carbo & Taxol vs Carbo & Taxol for Optimally Debulked, Advanced Endometrial Ca	thru 2/28/11
	(IRB#10-041)	
GOG-261	A Randomized Phase III trial of Paclitaxel plus Carboplatin versus Ifosfamide Plus	IRB approved
	Paclitaxel in Chemotherapy-Naive Patients with Newly Diagnosed Stage I-IV,	thru 9/30/11
	Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus or	
	Ovary (IRB#10-237)	

OVARIAN/PERITONEAL/FALLOPIAN TUBE

GOG-212	Random Phase III Trial Of Maintenance Chemo Comparing 12, Monthly Cycles Of	IRB approved
	Single Agent Paclitaxel Vs No Treatment Until Documented Relapse In Advanced	thru 2/28/2011
	Ovarian Or Primary Peritoneal Cancer who achieve a CCR To Primary	
	Platinum/Taxane Chemo	
	(IRB#06-194)	
GOG-213	Phase III Randomized Controlled Trial of Platinum-Combination, Sequence-Depend	IRB approved
	Chemo & Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian	thru 10/11
	& Peritoneal Primary Cancer	
	(IRB#08-036)	
GOG-214	Phase II Double Blind Randomized Trial Evaluating the Biologic Effect of	IRB approved
	Levonorgestrel on the Ovarian Epithelium in Women at High Risk for Ovarian Cancer	thru 3/31/11
	(IRB#09-074)	
GOG-262	Randomized Phase III Trial of Every 3-Weeks Paclitaxel vs Dose Dense Weekly	IRB approved
	Paclitaxel in Combination with Carboplatin With or Without Concurrent and	thru 2/25/2012
	Consolidation Bevacizumab in the Treatment of Primary Stage III or IV Epithelial	
	Ovarian, Peritoneal or Fallopian Tube Cancer (IRB#10-281)	

MULTIPLE SITES

MICEIII EE DI	110		
GOG-136	Acquisition of Human Gyn Specimens to be used in Studying the Causes, Dx,	IRB approved	
	Prevention & Treatment of Cancer	thru 7/31/2011	
	(IRB#07-320)	I	